RESUMEN
Deficient anterior pituitary with common variable immune deficiency (DAVID) syndrome is a rare condition characterized by adrenocorticotropic hormone (ACTH) deficiency and primary hypogammaglobulinemia. It is due to heterozygous mutations of the nuclear factor kappa-B subunit 2 (NFKB2) gene. Only a few isolated cases have been reported since its first description by our team. Through the international multicenter GENHYPOPIT network, we identified a new case of DAVID syndrome. We then conducted an extensive review of the DAVID syndrome cases published from 2012 to 2022. A 7-year-old boy was diagnosed with symptomatic hypoglycemia revealing ACTH deficiency. Laboratory tests showed asymptomatic hypogammaglobulinemia. He harbored a heterozygous point mutation in NFKB2 gene (c.2600C > T, p.Ala867Val). His management included hydrocortisone replacement treatment, and he also received subcutaneous immunoglobulins during the Covid-19 pandemic. We analyzed 28 cases of DAVID syndrome with ACTH deficiency. ACTH deficiency was the only hormone deficiency in 79% of patients, but some patients harbored growth hormone (GH) and thyroid stimulating hormone (TSH) deficiencies. The first presenting symptoms were sinus/pulmonary infections (82%, mean age of 3 years) and alopecia (mean age of 4.7 years). ACTH deficiency was the third presenting condition (mean age at diagnosis of 8.6 years). All patients had hypogammaglobulinemia (decreased IgA and IgM levels), and 57% of patients had at least one autoimmune manifestation. Heterozygous mutations at the 3'end of the NFKB2 gene, coding for the C-terminal domain of the protein, were identified in all cases. Better knowledge of DAVID syndrome will help clinicians make an early diagnosis to avoid life-threatening complications.
Asunto(s)
Inmunodeficiencia Variable Común , Hormonas Adenohipofisarias , Adulto , Niño , Femenino , Humanos , Masculino , Hormona Adrenocorticotrópica/deficiencia , Agammaglobulinemia/complicaciones , Autoinmunidad , Inmunodeficiencia Variable Común/complicaciones , Inmunodeficiencia Variable Común/genética , Inmunodeficiencia Variable Común/inmunología , Inmunodeficiencia Variable Común/fisiopatología , Heterocigoto , Hormona de Crecimiento Humana/deficiencia , Infecciones/complicaciones , Madres , Mutación , Fenotipo , Hormonas Adenohipofisarias/deficiencia , Síndrome , Tirotropina/deficienciaRESUMEN
Background: Diagnostic delay in common variable immunodeficiency disorders (CVID) is considerable. There is no generally accepted symptom-recognition framework for its early detection. Objective: To systematically review all existing data on the clinical presentation of CVID. Methods: PubMed, EMBASE and Cochrane were searched for cohort studies, published January/1999-December/2019, detailing the clinical manifestations before, at and after the CVID-diagnosis. Results: In 51 studies (n=8521 patients) 134 presenting and 270 total clinical manifestations were identified. Recurrent upper and/or lower respiratory infections were present at diagnosis in 75%. Many patients had suffered severe bacterial infections (osteomyelitis 4%, meningitis 6%, septicemia 8%, mastoiditis 8%). Bronchiectasis (28%), lymphadenopathy (27%), splenomegaly (13%), inflammatory bowel disease (11%), autoimmune cytopenia (10%) and idiopathic thrombocytopenia (6%) were also frequently reported. A bimodal sex distribution was found, with male predominance in children (62%) and female predominance in adults (58%). 25% of CVID-patients developed other manifestations besides infections in childhood, this percentage was much higher in adults (62%). Immune-dysregulation features, such as granulomatous-lymphocytic interstitial lung disease and inflammatory bowel disease, were more prominent in adults. Conclusions: The shift from male predominance in childhood to female predominance in adults suggests differences in genetic and environmental etiology in CVID and has consequences for pathophysiologic studies. We confirm the high frequency of respiratory infections at presentation, but also show a high incidence of severe bacterial infections such as sepsis and meningitis, and immune dysregulation features including lymphoproliferative, gastrointestinal and autoimmune manifestations. Early detection of CVID may be improved by screening for antibody deficiency in patients with these manifestations.
Asunto(s)
Bronquiectasia/epidemiología , Inmunodeficiencia Variable Común/fisiopatología , Linfadenopatía/epidemiología , Meningitis/epidemiología , Infecciones del Sistema Respiratorio/epidemiología , Adulto , Factores de Edad , Autoinmunidad , Niño , Inmunodeficiencia Variable Común/epidemiología , Humanos , Incidencia , Fenotipo , Factores SexualesRESUMEN
Objectives: Common variable immunodeficiency (CVID) is the most common symptomatic inborn error of immunity characterized by variable clinical manifestations. Methods: Web of Science, Scopus, and PubMed databases were searched systemically to find eligible studies from the earliest available date to February 2020 with standard keywords. Pooled estimates of the autoimmunity prevalence and the corresponding 95% confidence intervals (CI) were calculated using random-effects models. Results: The overall prevalence of autoimmunity was 29.8% (95% CI: 26.4-33.3; I2 = 82.8%). The prevalences of hematologic autoimmune diseases, autoimmune gastrointestinal disorders, autoimmune rheumatologic disorders, autoimmune skin disorders, and autoimmune endocrinopathy in CVID patients were 18.9%, 11.5%, 6.4%, 5.9%), and 2.5%, respectively. There were significantly higher lymphocyte, CD3 + T cell, and CD4 + T cell count among CVID patients without autoimmunity (p< 0.05). Furthermore, failure to thrive, organomegaly, enteropathy, and meningitis was significantly higher in CVID patients with autoimmunity(p< 0.05). Conclusions: Many CVID patients could present with autoimmunity as part of the disease or even as the first or only clinical manifestation of the disease. Care providers may need to pay particular attention to the possible association of these two disorders since the co-occurrence of CVID and autoimmunity could be a misleading clue.
Asunto(s)
Autoinmunidad , Inmunodeficiencia Variable Común/inmunología , Enfermedades Autoinmunes/diagnóstico , Enfermedades Autoinmunes/epidemiología , Enfermedades Autoinmunes/inmunología , Enfermedades Autoinmunes/fisiopatología , Inmunodeficiencia Variable Común/diagnóstico , Inmunodeficiencia Variable Común/epidemiología , Inmunodeficiencia Variable Común/fisiopatología , Humanos , PrevalenciaRESUMEN
BACKGROUND AND AIMS: Data from animals suggest that immunoglobulins G (IgG) play a mechanistic role in atherosclerosis and diabetes through endothelial dysfunction and insulin resistance. Patients with common variable immunodeficiency (CVID), who have low circulating levels of IgG and are treated with intravenous polyclonal IgG (IVIgG), may provide an ideal model to clarify whether circulating IgG modulate endothelial function and affect insulin sensitivity in humans. METHODS AND RESULTS: We studied 24 patients with CVID and 17 matched healthy controls (HC). Endothelial function was evaluated as flow mediated dilation (FMD) of the brachial artery at baseline and 1, 7, 14, and 21 days after IVIgG infusion in the CVID patients. We measured also plasma glucose, insulin, and calculated the HOMA-IR index. We also investigated the role of human IgG on the production of Nitric Oxide (NO) in vitro in Human Coronary Artery Endothelial Cells (HCAEC). Compared to HC, FMD of CVID patients was significantly impaired at baseline (9.4 ± 0.9 and 7.6 ± 0.6% respectively, p < 0.05) but rose above normal levels 1 and 7 days after IVIgG infusion to return at baseline at 14 and 21 days. Serum insulin concentration and HOMA-IR index dropped by 50% in CVID patients after IVIgG (p < 0.002 vs. baseline). In vitro IgG stimulated NO production in HCAEC. CONCLUSIONS: Reduced IgG levels are associated with endothelial dysfunction and IVIgG stimulates endothelial function directly while improving insulin sensitivity. The current findings may suggest an anti-atherogenic role of human IgG.
Asunto(s)
Arteria Braquial/efectos de los fármacos , Inmunodeficiencia Variable Común/tratamiento farmacológico , Endotelio Vascular/efectos de los fármacos , Inmunoglobulina G/administración & dosificación , Inmunoglobulinas Intravenosas/administración & dosificación , Resistencia a la Insulina , Vasodilatación/efectos de los fármacos , Adolescente , Biomarcadores/sangre , Glucemia/efectos de los fármacos , Glucemia/metabolismo , Arteria Braquial/metabolismo , Arteria Braquial/fisiopatología , Estudios de Casos y Controles , Células Cultivadas , Inmunodeficiencia Variable Común/sangre , Inmunodeficiencia Variable Común/fisiopatología , Endotelio Vascular/metabolismo , Endotelio Vascular/fisiopatología , Femenino , Humanos , Infusiones Intravenosas , Insulina/sangre , Masculino , Óxido Nítrico/metabolismo , Factores de Tiempo , Resultado del Tratamiento , Adulto JovenRESUMEN
Immune Thrombocitopenic Purpura (ITP) is an autoimmune disease characterized by antibody-mediated platelet destruction and variable reduced platelet production. Besides antibody-mediated platelet destruction, new pathogenic mechanisms have been reported to be involved in reducing platelet count. Among these, desialylation is one of the most recent and innovative mechanisms that has been found to be implied, at least in part, in non-antibody mediated platelet clearance. Common Variable Immunodeficiency (CVID) is the most common Primary Immunodeficiency seen in clinical practice. About 25-30% of CVID patients are affected by autoimmune manifestation, among which ITP is the most common. Little is know about pathophysiological mechanisms that lead to ITP in CVID. Given the poor antibody production typical of CVID patients, we aimed at verifying whether platelet desialylation could be responsible for CVID associated thrombocytopenia. According to our results, we may suggest that in CVID patients, ITP is due to a decreased bone marrow platelets production, rather than an increased peripheral platelet destruction, which is more common in patients with primary ITP. An increased platelet desialylation does not appear to be implicated in the thrombocytopenia secondary to CVID, while it is implicated in the pathogenesis of primary ITP. Nevertheless an intriguing aspect has emerged from this study: regardless the presence of thrombocytopenia, the majority of CVID patients present a double platelet population as far as desialylation concerns, whilst no one of the healthy donors and of the patients with primary ITP shows a similar characteristic.
Asunto(s)
Inmunodeficiencia Variable Común , Púrpura Trombocitopénica Idiopática , Anticuerpos , Plaquetas/patología , Inmunodeficiencia Variable Común/patología , Inmunodeficiencia Variable Común/fisiopatología , Humanos , Púrpura Trombocitopénica Idiopática/patología , Púrpura Trombocitopénica Idiopática/fisiopatologíaRESUMEN
Common variable immunodeficiency (CVID) is the most frequent primary immunodeficiency (PID) in adulthood and is characterized by severe reduction of immunoglobulin serum levels and impaired antibody production in response to vaccines and pathogens. Beyond the susceptibility to infections, CVID encompasses a wide spectrum of clinical manifestations related to a complex immune dysregulation that also affects liver. Although about 50% CVID patients present persistently deranged liver function, burden, and nature of liver involvement have not been systematically investigated in most cohort studies published in the last decades. Therefore, the prevalence of liver disease in CVID widely varies depending on the study design and the sampling criteria. This review seeks to summarize the evidence about the most relevant causes of liver involvement in CVID, including nodular regenerative hyperplasia (NRH), infections and malignancies. We also describe the clinical features of liver disease in some monogenic forms of PID included in the clinical spectrum of CVID as ICOS, NFKB1, NFKB2, CTLA-4, PI3Kδ pathway, ADA2, and IL21-R genetic defects. Finally, we discuss the clinical applications of the various diagnostic tools and the possible therapeutic approaches for the management of liver involvement in the context of CVID.
Asunto(s)
Inmunodeficiencia Variable Común/fisiopatología , Infecciones/fisiopatología , Hepatopatías/fisiopatología , Neoplasias Hepáticas/fisiopatología , Hígado/patología , Antígeno CTLA-4/genética , Inmunodeficiencia Variable Común/genética , Humanos , Hiperplasia , Proteína Coestimuladora de Linfocitos T Inducibles/genética , Infecciones/genética , Hepatopatías/genética , Neoplasias Hepáticas/genética , FN-kappa B/genética , FenotipoRESUMEN
Common variable immunodeficiency syndrome (CVID) is a heterogeneous disorder characterised by diminished levels of IgG, IgA and/or IgM, and recurrent bacterial infections. Sinopulmonary infections are most commonly reported followed by gastrointestinal (GI) infections. GI tract represents the largest immune organ with abundance of lymphoid cells, its involvement can manifest variably ranging from asymptomatic involvement to florid symptoms and signs. Diffuse nodular lymphoid hyperplasia (DNLH) of the GI tract is characterised by numerous small polypoid nodules of variable size in the small intestine, large intestine or both. It is commonly seen in association to immunodeficiency states such as CVID, IgA deficiency and chronic infections due to Giardia lamblia and Helicobacter pylori and cryptosporidiosis. Repetitive antigenic stimulation leads to lymphoid hyperplasia. We herein describe a case of DNLH of the intestine and another case of duodenal cytomegalovirus (CMV) infection associated with CVID.
Asunto(s)
Inmunodeficiencia Variable Común/virología , Infecciones por Citomegalovirus/complicaciones , Diarrea/virología , Duodeno/patología , Hiperplasia/virología , Intestino Delgado/patología , Trastornos Linfoproliferativos/virología , Adulto , Antivirales/uso terapéutico , Inmunodeficiencia Variable Común/tratamiento farmacológico , Inmunodeficiencia Variable Común/fisiopatología , Infecciones por Citomegalovirus/fisiopatología , Duodeno/virología , Endoscopía del Sistema Digestivo , Ganciclovir/uso terapéutico , Humanos , Hiperplasia/tratamiento farmacológico , Hiperplasia/fisiopatología , Inmunoglobulinas Intravenosas/uso terapéutico , Intestino Delgado/virología , Trastornos Linfoproliferativos/tratamiento farmacológico , Trastornos Linfoproliferativos/fisiopatología , Masculino , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
Common variable immune deficiency (CVID) is a primary immunodeficiency disorder that is associated with abnormal liver function tests, however advanced liver disease is uncommon. Hepatopulmonary syndrome (HPS) is a rare but debilitating complication of CVID-associated liver disease. We report a case of CVID complicated by HPS that was successfully treated with orthotopic liver transplant, with the patient recovering to normal hepatic function and successfully weaning off domiciliary oxygen post-transplantation.
Asunto(s)
Inmunodeficiencia Variable Común/complicaciones , Síndrome Hepatopulmonar/cirugía , Trasplante de Hígado/métodos , Inmunodeficiencia Variable Común/fisiopatología , Femenino , Síndrome Hepatopulmonar/inmunología , Humanos , Hígado/fisiopatología , Persona de Mediana Edad , Resultado del TratamientoAsunto(s)
Inmunodeficiencia Variable Común/tratamiento farmacológico , Factores Inmunológicos/uso terapéutico , Enfermedades Pulmonares Intersticiales/tratamiento farmacológico , Rituximab/uso terapéutico , Adulto , Inmunodeficiencia Variable Común/fisiopatología , Femenino , Humanos , Enfermedades Pulmonares Intersticiales/fisiopatología , Masculino , Pruebas de Función Respiratoria , Resultado del Tratamiento , Adulto JovenAsunto(s)
Inmunodeficiencia Variable Común , Ciclofosfamida/administración & dosificación , Inmunoglobulinas Intravenosas/administración & dosificación , Prednisona/administración & dosificación , Síndrome de Sweet , Adulto , Biopsia/métodos , Inmunodeficiencia Variable Común/complicaciones , Inmunodeficiencia Variable Común/diagnóstico , Inmunodeficiencia Variable Común/tratamiento farmacológico , Inmunodeficiencia Variable Común/fisiopatología , Diagnóstico Diferencial , Femenino , Humanos , Factores Inmunológicos/administración & dosificación , Piel/patología , Síndrome de Sweet/complicaciones , Síndrome de Sweet/diagnóstico , Síndrome de Sweet/tratamiento farmacológico , Síndrome de Sweet/fisiopatología , Resultado del TratamientoRESUMEN
Common Variable Immune Deficiency (CVID) is rare. It is a constitutional deficit of humoral immunity characterized by recurrent bacterial infections and by increased frequency of tumors, autoimmune or granulomatous diseases. Gastrointestinal manifestations are very variable and sometimes reveal common variable immune deficiency. We report the case of a 31-year old patient with a history of childhood recurrent respiratory infections complicated by bronchiectasis and with a 3-year history of recurrent glairy diarrhea. Etiological balance was in favor of CVID with autoimmune manifestation (vitiligo). Patient's treatment was based on monthly immunoglobulin (Ig) infusions with favorable outcome at 2-year follow-up.
Asunto(s)
Inmunodeficiencia Variable Común/diagnóstico , Enfermedades Gastrointestinales/etiología , Vitíligo/etiología , Adulto , Infecciones Bacterianas/etiología , Inmunodeficiencia Variable Común/inmunología , Inmunodeficiencia Variable Común/fisiopatología , Diarrea/etiología , Estudios de Seguimiento , Humanos , Inmunoglobulinas/administración & dosificación , MasculinoRESUMEN
Many patients with primary immunodeficiency (PID) who have antibody deficiency develop progressive lung disease due to underlying subclinical infection and inflammation. To understand how these patients are monitored we conducted a retrospective survey based on patient records of 13 PID centres across Europe, regarding the care of 1061 adult and 178 paediatric patients with PID on immunoglobulin (Ig) G replacement. The most common diagnosis was common variable immunodeficiency in adults (75%) and hypogammaglobulinaemia in children (39%). The frequency of clinic visits varied both within and between centres: every 1-12 months for adult patients and every 3-6 months for paediatric patients. Patients diagnosed with lung diseases were more likely to receive pharmaceutical therapies and received a wider range of therapies than patients without lung disease. Variation existed between centres in the frequency with which some clinical and laboratory monitoring tests are performed, including exercise tests, laboratory testing for IgG subclass levels and specific antibodies, and lung function tests such as spirometry. Some tests were carried out more frequently in adults than in children, probably due to difficulties conducting these tests in younger children. The percentage of patients seen regularly by a chest physician, or who had microbiology tests performed following chest and sinus exacerbations, also varied widely between centres. Our survey revealed a great deal of variation across Europe in how frequently patients with PID visit the clinic and how frequently some monitoring tests are carried out. These results highlight the urgent need for consensus guidelines on how to monitor lung complications in PID patients.
Asunto(s)
Síndromes de Inmunodeficiencia/fisiopatología , Enfermedades Pulmonares/complicaciones , Sistema Respiratorio/fisiopatología , Adulto , Agammaglobulinemia/fisiopatología , Atención Ambulatoria , Infecciones Asintomáticas/epidemiología , Niño , Inmunodeficiencia Variable Común/fisiopatología , Europa (Continente) , Femenino , Humanos , Inmunización Pasiva , Inmunoglobulina G/uso terapéutico , Inmunoglobulinas/uso terapéutico , Síndromes de Inmunodeficiencia/complicaciones , Síndromes de Inmunodeficiencia/inmunología , Síndromes de Inmunodeficiencia/terapia , Enfermedades Pulmonares/diagnóstico , Enfermedades Pulmonares/inmunología , Enfermedades Pulmonares/prevención & control , Masculino , Registros Médicos , Guías de Práctica Clínica como Asunto , Estudios Retrospectivos , EspirometríaRESUMEN
PURPOSE: Common variable immunodeficiency (CVID) is a complex, heterogeneous immunodeficiency characterized by hypogammaglobulinemia, recurrent infections, and poor antibody response to vaccination. While antibiotics and immunoglobulin prophylaxis have significantly reduced infectious complications, non-infectious complications of autoimmunity, inflammatory lung disease, enteropathy, and malignancy remain of great concern. Previous studies have suggested that CVID patients diagnosed in childhood are more severely affected by these complications than adults diagnosed later in life. We sought to discern whether the rates of various infectious and non-infectious conditions differed between pediatric-diagnosed (ages 17 or younger) versus adult-diagnosed CVID (ages 18 or older). METHODS: Using the United States Immunodeficiency Network (USIDNET) database, we performed a retrospective analysis of 457 children and adults with CVID, stratified by age at diagnosis. Chi-squared testing was used to compare pediatric versus adult groups. RESULTS: After correcting for multiple comparisons, we identified few statistically significant differences (p ≤ 0.0004) between pediatric and adult groups. Pediatric-onset CVID patients had more frequent diagnoses of otitis media, developmental delay, and failure to thrive compared with adult-onset CVID patients. Adult CVID patients were more frequently diagnosed with bronchitis, arthritis, depression, and fatigue. Diagnoses of autoimmunity, lymphoma, and other malignancies were higher in adults but not to a significant degree. Serum immunoglobulins (IgG, IgA, and IgM) and lymphocyte subsets did not differ significantly between the two groups. When complications of infections and co-morbid conditions were viewed categorically, there were few differences between pediatric-onset and adult-onset CVID patients. CONCLUSIONS: These results suggest that pediatric CVID is not a distinct phenotype. Major features were comparable across the groups. This study underscores the need for continued longitudinal study of pediatric and early-onset CVID patients to further characterize accrual of features over time.
Asunto(s)
Artritis/fisiopatología , Bronquitis/fisiopatología , Inmunodeficiencia Variable Común/fisiopatología , Depresión/fisiopatología , Discapacidades del Desarrollo/fisiopatología , Insuficiencia de Crecimiento/fisiopatología , Otitis Media/fisiopatología , Adolescente , Adulto , Edad de Inicio , Anciano , Anciano de 80 o más Años , Artritis/epidemiología , Autoinmunidad , Bronquitis/epidemiología , Transformación Celular Neoplásica , Niño , Preescolar , Inmunodeficiencia Variable Común/epidemiología , Bases de Datos Factuales , Depresión/epidemiología , Discapacidades del Desarrollo/epidemiología , Insuficiencia de Crecimiento/epidemiología , Femenino , Humanos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Otitis Media/epidemiología , Fenotipo , Estudios Retrospectivos , Estados Unidos/epidemiología , Adulto JovenRESUMEN
BACKGROUND: The ability of anti-cytokine antibodies to play a disease-causing role in the pathogenesis of immunodeficiencies is widely accepted. The aim of this study was to investigate whether autoantibodies against BAFF (important B cell survival signal), APRIL (important plasma cell survival signal), or Interleukin-21 (important cytokine for immunoglobulin class switch) present an alternative mechanism for the development of the following primary antibody deficiencies (PADs): common variable immune deficiency (CVID) or selective IgA deficiency (sIgAD). RESULTS: Two hundred thirty-two sera from patients with PADs were screened for autoantibodies against cytokines by ELISA. Statistical data analysis yielded a significant difference (p < 0.01) between the healthy donor sera and both PAD cohorts. The analysis was deepened by subdividing the patient collective into groups with distinct B cell phenotypes but no significant differences were found. For selected sera with notable high ELISA-read outs functional analysis ensued. Anti-BAFF and anti-APRIL antibodies were further examined by a B cell survival assay, whilst the functional relevance of putative anti-IL-21 autoantibodies was investigated by means of a STAT3 phosphorylation assay. However, the results of these experiments revealed no discernible functional effect. CONCLUSION: Whilst statistical analysis of ELISA results showed significant differences between patients and healthy controls, in our set of patients functional tests yielded no evidence for an involvement of autoantibodies against BAFF, APRIL, or IL-21 in the pathogenesis of CVID or sIgAD.
Asunto(s)
Autoanticuerpos/fisiología , Factor Activador de Células B/inmunología , Síndromes de Inmunodeficiencia/inmunología , Síndromes de Inmunodeficiencia/fisiopatología , Interleucinas/inmunología , Miembro 13 de la Superfamilia de Ligandos de Factores de Necrosis Tumoral/inmunología , Autoanticuerpos/sangre , Subgrupos de Linfocitos B/citología , Subgrupos de Linfocitos B/inmunología , Supervivencia Celular , Inmunodeficiencia Variable Común/inmunología , Inmunodeficiencia Variable Común/fisiopatología , Humanos , Deficiencia de IgA/inmunología , Deficiencia de IgA/fisiopatología , Interleucinas/metabolismo , Fosforilación , Factor de Transcripción STAT3/inmunologíaRESUMEN
Common variable immunodeficiency (CVID) is a diagnostic category of primary immunodeficiency (PID) which may present with heterogeneous disorders including recurrent infections, autoimmunity, granulomatous diseases, lymphoid and other types of malignancies. Generally, the incidence of malignancy in CVID patients is around 1.5-20.7% and usually occurs during the 4th-6th decade of life. Non-Hodgkin lymphoma is the most frequent malignancy, followed by epithelial tumours of stomach, breast, bladder and cervix. The exact pathological mechanisms for cancer development in CVID are not fully determined; however, several mechanisms including impaired genetic stability, genetic predisposition, immune dysregulation, impaired clearance of oncogenic viruses and bacterial infections, and iatrogenic causes have been proposed to contribute to the high susceptibility of these patients to malignancies.
Asunto(s)
Inmunodeficiencia Variable Común/epidemiología , Sistema Inmunológico , Neoplasias/epidemiología , Factores de Edad , Inmunodeficiencia Variable Común/complicaciones , Inmunodeficiencia Variable Común/fisiopatología , Interacción Gen-Ambiente , Predisposición Genética a la Enfermedad , Homeostasis , Humanos , Incidencia , Neoplasias/complicaciones , Neoplasias/fisiopatologíaAsunto(s)
Alérgenos/inmunología , Inmunodeficiencia Variable Común/epidemiología , Hipersensibilidad a las Drogas/epidemiología , Penicilinas/inmunología , Adolescente , Adulto , Anciano , Inmunodeficiencia Variable Común/fisiopatología , Hipersensibilidad a las Drogas/fisiopatología , Exantema , Femenino , Humanos , Inmunoglobulina E/metabolismo , Masculino , Persona de Mediana Edad , Prevalencia , Autoinforme , Pruebas Cutáneas , Estados Unidos/epidemiología , Adulto JovenRESUMEN
BACKGROUND: Common variable immunodeficiency (CVID) is a heterogeneous disease, characterised by hypogammaglobulinaemia leading to recurrent infections and various complications. The aim of this study was to classify CVID patients based on four known classifications (Paris, Freiburg, EUROclass, and B-cell patterns) by measurement of B-cell subsets and to assess the relation of each classification with clinical manifestations. METHODS: We measured all B-cell subsets as both absolute count and percentage in 30 CVID patients and 30 healthy individuals using four-colour flow cytometry. Moreover, we evaluated antibody responses to pneumococcal vaccine in patients. RESULTS: A significant reduction in percentage of terminal B-cell subsets (total, marginal zone-like, switched memory, IgM-only memory, total memory B-cells and plasmablast) and absolute count of all B-cell subsets along with a strong increase in CD21low B-cells has been observed in patients. Patients with splenomegaly and hepatomegaly clustered in group Ia, smB+21low and group 1 based on known classifications, and significantly tended to have a decreased transitional and marginal zone-like B-cells count, as well as an increase in CD21low B-cell counts. Patients with lymphadenopathy, bronchiectasis and allergy had a significant decrease in absolute count of total memory, switched memory and total B-cells, respectively. CONCLUSION: Classification of patients could provide useful information to guide clinicians in long-term follow-up of CVID patients. Our data demonstrate that it may be more accurate to use absolute counts of B-cell subpopulations in CVID patients because absolute counts of B-cell subsets are more associated with clinical manifestations compared with their percentage and also four known classifications.
Asunto(s)
Subgrupos de Linfocitos B/inmunología , Inmunodeficiencia Variable Común/inmunología , Adolescente , Adulto , Bronquiectasia , Niño , Inmunodeficiencia Variable Común/clasificación , Inmunodeficiencia Variable Común/fisiopatología , Femenino , Hepatomegalia , Humanos , Memoria Inmunológica , Inmunofenotipificación , Linfadenopatía , Recuento de Linfocitos , Masculino , Persona de Mediana Edad , Receptores de Complemento 3d/metabolismo , Esplenomegalia , Adulto JovenRESUMEN
Although common variable immunodeficiency (CVID) has long been considered as a group of primary Ab deficiencies, growing experimental data now suggest a global disruption of the entire adaptive immune response in a segment of patients. Oligoclonality of the TCR repertoire was previously demonstrated; however, the manner in which it relates to other B cell and T cell findings reported in CVID remains unclear. Using a combination approach of high-throughput TCRß sequencing and multiparametric flow cytometry, we compared the TCR repertoire diversity between various subgroups of CVID patients according to their B cell immunophenotypes. Our data suggest that the reduction in repertoire diversity is predominantly restricted to those patients with severely reduced class-switched memory B cells and an elevated level of CD21(lo) B cells (Freiburg 1a), and may be driven by a reduced number of naive T cells unmasking underlying memory clonality. Moreover, our data indicate that this loss in repertoire diversity progresses with advancing age far exceeding the expected physiological rate. Radiological evidence supports the loss in thymic volume, correlating with the decrease in repertoire diversity. Evidence now suggests that primary thymic failure along with other well-described B cell abnormalities play an important role in the pathophysiology in Freiburg group 1a patients. Clinically, our findings emphasize the integration of combined B and T cell testing to identify those patients at the greatest risk for infection. Future work should focus on investigating the link between thymic failure and the severe reduction in class-switched memory B cells, while gathering longitudinal laboratory data to examine the progressive nature of the disease.
Asunto(s)
Inmunodeficiencia Variable Común/inmunología , Receptores de Antígenos de Linfocitos T alfa-beta/genética , Receptores de Antígenos de Linfocitos T alfa-beta/inmunología , Linfocitos T/inmunología , Factores de Edad , Linfocitos B/inmunología , Inmunodeficiencia Variable Común/fisiopatología , Citometría de Flujo/métodos , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Cambio de Clase de Inmunoglobulina , Memoria Inmunológica , Inmunofenotipificación , Depleción Linfocítica , Persona de Mediana Edad , Receptores de Antígenos de Linfocitos T alfa-beta/metabolismo , Receptores de Complemento 3d/inmunología , Timo/patologíaRESUMEN
Common variable immunodeficiency (CVID) is a heterogeneous primary immunodeficiency disease, leading to recurrent bacterial airway infections and often also autoimmune complications. To shed light on the regulatory lymphocytes from these patients, we analyzed the levels of regulatory B (pro-B10) cell and regulatory T (Treg) cell subpopulations in PBMCs from twenty-six patients diagnosed with CVID using multi-color flowcytometry. Pro-B10 cells were induced by 48h in vitro stimulation prior to analysis. Suppressor function was measured on a subset of patients with splenomegaly and autoimmune complications. The levels of regulatory B and T cells were correlated to clinical manifestations, including autoimmunity, splenomegaly and CVID EUROclass subgroups. We demonstrate a significant association between elevated levels of pro-B10 cells, decreased levels of Tregs and autoimmune phenomena in CVID patients. The finding of marked abnormalities in regulatory lymphocyte populations contribute to our understanding of the pathogenesis of CVID and potentially be valuable in the clinical management and treatment of patients.